Abstract

Two new studies exploring PROTAC-mediated degradation of SMARCA2 for cancer therapy solve an apparently intractable selectivity challenge with SMARCA4 by utilising the requirement for a productive ternary complex between the protein, PROTAC and ligase complex.

Details

Title
A two-faced selectivity solution to target SMARCA2 for cancer therapy
Author
Harling, John D. 1   VIAFID ORCID Logo  ; Tinworth, Christopher P. 1   VIAFID ORCID Logo 

1  Dept. of Medicinal Chemistry, GSK, Stevenage, UK (GRID:grid.418236.a) (ISNI:0000 0001 2162 0389) 
Pages
515
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41467-023-36238-0
ProQuest document ID
2771199393
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.